GM
SUPN icon

GeoWealth Management’s Supernus Pharmaceuticals SUPN Stock Holding History

GeoWealth Management’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-604
Closed -$21.8K – 1720
2024
Q4 		$21.8K Sell
604
-10
-2% -$352 ﹤0.01% 1363
2024
Q3 		$19.1K Buy
+614
New +$19.2K ﹤0.01% 1286

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
GKIM
GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return

GeoWealth Management's SUPN Position: Q1 2025 in Review

GeoWealth Management sold out of Supernus Pharmaceuticals (SUPN) in Q1 2025, closing a stake of 604 shares — an estimated $21.8K sold.

GeoWealth Management first reported a position in SUPN in Q3 2024 and held it in 2 quarters. The position peaked at $21.8K in Q4 2024. 295 funds tracked by Wall St. Rank hold SUPN as of Q1 2025.

  • GeoWealth Management reported no remaining Supernus Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • GeoWealth Management sold 604 Supernus Pharmaceuticals shares in Q1 2025, an estimated $21.8K.
  • GeoWealth Management first reported a position in Supernus Pharmaceuticals in Q3 2024 and held it in 2 quarters.
  • GeoWealth Management's Supernus Pharmaceuticals position peaked at $21.8K in Q4 2024.
  • 295 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2025.

Based on GeoWealth Management's 13F filing for Q1 2025, filed 9 May 2025.